SCHEMBL2327344

SCHEMBL2327344

CCCC(CN[C@@H](CC)C(N)=O)CC(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.33
CA2 P00918 1/20 0.33
CACNA2D1 P54289 2/20 0.33
ADRA1A P35348 2/20 0.33
CACNB3 P54284 1/20 0.33
CACNA1C Q13936 1/20 0.33
PGR P06401 1/20 0.33
HTR2B P41595 1/20 0.33
CACNA2D2 Q9NY47 1/20 0.33
GPR84 Q9NQS5 4/20 0.32
ENPEP Q07075 2/20 0.32
CA12 O43570 1/20 0.31
CA9 Q16790 1/20 0.31
MMP9 P14780 1/20 0.31
MMP8 P22894 1/20 0.31
MMP13 P45452 1/20 0.31
S1PR2 O95136 1/20 0.31
S1PR1 P21453 1/20 0.31
CHRM1 P11229 1/20 0.31
AKR1A1 P14550 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21602746 1.00 CA1 (0.33) CA1CA2CACNA2D1ADRA1ACACNB3
SCHEMBL23311196 1.00 CA1 (0.33) CA1CA2CACNA2D1ADRA1ACACNB3
SCHEMBL20767989 1.00 CA1 (0.33) CA1CA2CACNA2D1ADRA1ACACNB3
SCHEMBL21602737 1.00 CA1 (0.33) CA1CA2CACNA2D1ADRA1ACACNB3
SCHEMBL2327334 1.00 CA1 (0.33) CA1CA2CACNA2D1ADRA1ACACNB3
Hydrochloric Acid SCHEMBL6778482 0.98 CA1 (0.33) CA1CA2CACNA2D1ADRA1ACACNB3
Oxalic Acid SCHEMBL23270124 0.97 CA1 (0.32) CA1CA2CACNA2D1ADRA1ACACNB3
Oxalic Acid SCHEMBL23270122 0.97 CA1 (0.32) CA1CA2CACNA2D1ADRA1ACACNB3
Maleic Acid SCHEMBL23270119 0.93 HCAR2 (0.32)
Maleic Acid SCHEMBL23270121 0.93 HCAR2 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110615744-B Buvalracetam intermediate and preparation method thereof 上海朴颐化学科技有限公司 2023-01-06 CN claimed
CN-110615744-A Buvalracetam intermediate and preparation method thereof 上海朴颐化学科技有限公司 2019-12-27 CN claimed
EP-1265862-B1 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB SA (BE) 2005-09-21 EP claimed
US-12365649-B2 Process for the preparation of brivaracetam ALIVUS LIFE SCIENCES LIMITED (IN) 2025-07-22 US disclosed
CN-112020498-B Buvalracetam intermediate, preparation method thereof and preparation method of Buvalracetam 上海朴颐化学科技有限公司 2024-04-02 CN disclosed
US-20240010618-A1 PROCESS FOR THE PREPARATION OF BRIVARACETAM ALIVUS LIFE SCIENCES LIMITED (IN) 2024-01-11 US disclosed
CN-110615744-B Buvalracetam intermediate and preparation method thereof 上海朴颐化学科技有限公司 2023-01-06 CN disclosed
US-11518741-B2 Brivaracetam intermediate, preparation method therefor, and preparation method for brivaracetam SHANGHAI PUYI CHEMICAL CO., LTD. (CN) 2022-12-06 US disclosed
US-11518741-B2 Brivaracetam intermediate, preparation method therefor, and preparation method for brivaracetam SHANGHAI PUYI CHEMICAL CO., LTD. (CN) 2022-12-06 US disclosed
US-20210253523-A1 BRIVARACETAM INTERMEDIATE, PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR BRIVARACETAM SHANGHAI PUYI CHEMICAL CO., LTD. (CN) 2021-08-19 US disclosed
US-20210253523-A1 BRIVARACETAM INTERMEDIATE, PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR BRIVARACETAM SHANGHAI PUYI CHEMICAL CO., LTD. (CN) 2021-08-19 US disclosed
EP-3812377-A1 BRIVARACETAM INTERMEDIATE, PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR BRIVARACETAM Shanghai Puyi Chemical Co., Ltd. (CN) 2021-04-28 EP disclosed
CN-111187175-A Method for preparing intermediate of brivaracetam by hydrogenation of microchannel reactor 上海朴颐化学科技有限公司 2020-05-22 CN disclosed
CN-110615744-A Buvalracetam intermediate and preparation method thereof 上海朴颐化学科技有限公司 2019-12-27 CN disclosed
CN-110615744-A Buvalracetam intermediate and preparation method thereof 上海朴颐化学科技有限公司 2019-12-27 CN disclosed
WO-2019242192-A1 BRIVARACETAM INTERMEDIATE, PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR BRIVARACETAM 上海朴颐化学科技有限公司 2019-12-26 WO disclosed
US-8338621-B2 Process for the preparation of 2-oxo-1-pyrrolidine derivatives UCB S.A. (BE) 2012-12-25 US disclosed
EP-1806339-B1 Process for the preparation of 2-oxo-1-pyrrolidine derivatives UCB PHARMA SA (BE) 2011-08-17 EP disclosed
US-20080009638-A1 PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES UCB S.A. (BE) 2008-01-10 US disclosed
EP-1806339-A1 Process for the preparation of 2-oxo-1-pyrrolidine derivatives UCB, S.A. (BE) 2007-07-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009638-A1 PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES CYP2F1, CYP3A5, SULT1E1 CA1 2079/4885CA2 1508/4885CACNA2D1 352/4885
US-11518741-B2 Brivaracetam intermediate, preparation method therefor, and preparation method for brivaracetam CYP51A1, FAR1, POR CA1 3969/4885CA2 1455/4885CACNA2D1 319/4885
US-20210253523-A1 BRIVARACETAM INTERMEDIATE, PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR BRIVARACETAM CYP51A1, FAR1, POR CA1 3969/4885CA2 1455/4885CACNA2D1 319/4885
US-12365649-B2 Process for the preparation of brivaracetam CYP2C19, CYP2B6, POR CA1 2579/4885CA2 453/4885CACNA2D1 1281/4885
US-20240010618-A1 PROCESS FOR THE PREPARATION OF BRIVARACETAM CYP2C19, CYP2B6, POR CA1 2579/4885CA2 453/4885CACNA2D1 1281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.